Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03374254
Title Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal cancer

Therapies

Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.